Tryp Therapeutics Partners with Calvert Labs to Conduct Exploratory Studies for Proprietary Psilocybin Formulations
San Diego, California–(Newsfile Corp. – August 10, 2021) – Tryp Therapeutics (CNSX:TRYP.CN) (OTCQB:TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Calvert Labs to design and execute exploratory studies related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PFN TM ) program. Calvert Labs , […]
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:RVVTF) (CNSX:RVV.CN) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s psychedelics development and clinical programs with a focus on psilocybin. Michael Frank, CEO of the Company, commented, […]
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
NEW YORK , Aug. 10, 2021 /PRNewswire/ — MindMed (NASDAQ:MNMD) (NEO:MMED) (DE:MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin , Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years conducting clinical research on pain. He is currently Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, and Professor in […]
